Credit Suisse’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $20.6M | Sell |
4,547,315
-30,935
| -0.7% | -$140K | 0.02% | 622 |
|
|
2023
Q4 | $26.1M | Buy |
4,578,250
+5,273
| +0.1% | +$30.1K | 0.03% | 579 |
|
|
2023
Q3 | $21M | Sell |
4,572,977
-1,609
| -0% | -$7.4K | 0.02% | 620 |
|
|
2023
Q2 | $29.6M | Sell |
4,574,586
-33,574
| -0.7% | -$217K | 0.03% | 544 |
|
|
2023
Q1 | $34.7M | Buy |
4,608,160
+507,665
| +12% | +$3.83M | 0.04% | 504 |
|
|
2022
Q4 | $41.5M | Sell |
4,100,495
-976
| -0% | -$9.89K | 0.04% | 442 |
|
|
2022
Q3 | $40.6M | Buy |
4,101,471
+1,507,513
| +58% | +$14.9M | 0.05% | 433 |
|
|
2022
Q2 | $27.6M | Sell |
2,593,958
-60,756
| -2% | -$647K | 0.03% | 573 |
|
|
2022
Q1 | $25.9M | Buy |
2,654,714
+32,389
| +1% | +$316K | 0.02% | 674 |
|
|
2021
Q4 | $37.5M | Sell |
2,622,325
-180,086
| -6% | -$2.58M | 0.02% | 571 |
|
|
2021
Q3 | $56.2M | Buy |
2,802,411
+166,638
| +6% | +$3.34M | 0.03% | 433 |
|
|
2021
Q2 | $58M | Buy |
2,635,773
+364,973
| +16% | +$8.03M | 0.03% | 446 |
|
|
2021
Q1 | $77.1M | Buy |
+2,270,800
| New | +$77.1M | 0.04% | 386 |
|